Xymeg Tablet contains Megestrol 160 mg, a synthetic progestin used primarily in the management of anorexia, cachexia, or significant weight loss associated with chronic illnesses such as cancer and AIDS. Megestrol acts by stimulating appetite and promoting weight gain, thereby improving nutritional status and quality of life in patients experiencing severe weight loss. It is also employed as an adjunctive therapy in hormone-responsive cancers, including breast and endometrial carcinoma, due to its antineoplastic and antiproliferative properties. The tablet is administered orally, with dosage tailored according to the clinical condition and patient response. Common adverse effects may include fluid retention, thromboembolic events, hypertension, and gastrointestinal disturbances; therefore, careful monitoring is advised during therapy. Contraindications include known hypersensitivity to Megestrol or any tablet components, active thromboembolic disorders, and pregnancy. Caution is warranted in patients with cardiovascular disease, diabetes mellitus, or hepatic impairment. Xymeg Tablet should be used under strict medical supervision, with periodic evaluation of therapeutic efficacy and adverse effects to optimize patient outcomes. It is essential to adhere to prescribed dosage and duration to minimize risks and maximize benefits in the management of cachexia and hormone-dependent malignancies.